33 related articles for article (PubMed ID: 7743513)
1. Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells.
Hernandez VA; Carvajal-Moreno J; Wang X; Pietrzak M; Yalowich JC; Elton TS
PLoS One; 2022; 17(5):e0265794. PubMed ID: 35617303
[TBL] [Abstract][Full Text] [Related]
2. Towards establishment of a plant-based model to assess the novel anti-cancerous lead molecule(s): An in silico, in vivo and in vitro assessment of some potential anti-cancerous drugs on Lathyrus sativus L.
Samanta A; Banerjee S; Maity TR; Jahnavi J; Datta S
Protoplasma; 2022 Nov; 259(6):1455-1466. PubMed ID: 35195768
[TBL] [Abstract][Full Text] [Related]
3. Effects of DNA topoisomerase IIα splice variants on acquired drug resistance.
Elton TS; Ozer HG; Yalowich JC
Cancer Drug Resist; 2020; 3(2):161-170. PubMed ID: 32566920
[TBL] [Abstract][Full Text] [Related]
4. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II
Kania EE; Carvajal-Moreno J; Hernandez VA; English A; Papa JL; Shkolnikov N; Ozer HG; Yilmaz AS; Yalowich JC; Elton TS
Mol Pharmacol; 2020 Mar; 97(3):159-170. PubMed ID: 31836624
[TBL] [Abstract][Full Text] [Related]
5. Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives.
Talati C; Sweet KL
Int J Hematol Oncol; 2018 Oct; 7(3):IJH04. PubMed ID: 30405902
[TBL] [Abstract][Full Text] [Related]
6. The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase II
Kanagasabai R; Karmahapatra S; Kientz CA; Yu Y; Hernandez VA; Kania EE; Yalowich JC; Elton TS
Mol Pharmacol; 2018 May; 93(5):515-525. PubMed ID: 29514855
[TBL] [Abstract][Full Text] [Related]
7. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
8. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.
Tamaichi H; Sato M; Porter AC; Shimizu T; Mizutani S; Takagi M
Cancer Sci; 2013 Feb; 104(2):178-84. PubMed ID: 23163762
[TBL] [Abstract][Full Text] [Related]
9. Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain.
McClendon AK; Gentry AC; Dickey JS; Brinch M; Bendsen S; Andersen AH; Osheroff N
Biochemistry; 2008 Dec; 47(50):13169-78. PubMed ID: 19053267
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase II, genotoxicity, and cancer.
McClendon AK; Osheroff N
Mutat Res; 2007 Oct; 623(1-2):83-97. PubMed ID: 17681352
[TBL] [Abstract][Full Text] [Related]
11. Nuclear interactions of topoisomerase II alpha and beta with phospholipid scramblase 1.
Wyles JP; Wu Z; Mirski SE; Cole SP
Nucleic Acids Res; 2007; 35(12):4076-85. PubMed ID: 17567603
[TBL] [Abstract][Full Text] [Related]
12. DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Berney DM; Shamash J; Gaffney J; Jordan S; Oliver RT
Br J Cancer; 2002 Sep; 87(6):624-9. PubMed ID: 12237772
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
Kreisholt J; Sorensen M; Jensen PB; Nielsen BS; Andersen CB; Sehested M
Br J Cancer; 1998 May; 77(9):1469-73. PubMed ID: 9652763
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line.
Mirski SE; Cole SP
Cancer Res; 1995 May; 55(10):2129-34. PubMed ID: 7743513
[TBL] [Abstract][Full Text] [Related]
15. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
Yu Q; Mirski SE; Sparks KE; Cole SP
Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
[TBL] [Abstract][Full Text] [Related]
16. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
[TBL] [Abstract][Full Text] [Related]
17. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase expression in cancer cell lines and clinical samples.
Doyle LA
Cancer Chemother Pharmacol; 1994; 34 Suppl():S32-40. PubMed ID: 8070025
[TBL] [Abstract][Full Text] [Related]
19. The role of DNA topoisomerases II in drug resistance.
Alton PA; Harris AL
Br J Haematol; 1993 Oct; 85(2):241-5. PubMed ID: 8280597
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
